

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Peter Anthony CROOKS, et al.

Serial No.:

Group Art Unit:

Filed: June 15, 2001

Examiner:

For: AGMATINE AND AGMATINE ANALOGS IN THE TREATMENT OF EPILEPSY,
SEIZURE AND ELECTROCONVULSIVE DISORDERS

JC997 U.S. PTO
09/881215
06/15/01

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231


Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted,

MCDERMOTT, WILL & EMERY



Daniel Bucca, Ph.D.
Registration No. 42,368

600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 DB:prp
Date: June 15, 2001
Facsimile: (202) 756-8087